Nano Dimension Ltd (NNDM)

Form PREC14A - Preliminary proxy statements, contested solicitations

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Nano Dimension and Infinite Epigenetics Provide Additional Information Regarding Proposed Business Combination

WALTHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,”...

Murchinson Criticizes the Nano Dimension Board of Directors’ Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics

Believes the Proposed Transaction Represents a Misallocation of Corporate Resources That Would Significantly Dilute Existing Shareholders Finds...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Murchinson Invites Fellow Nano Dimension Shareholders to Participate In a Survey: What Trendy Industry Is the Board, Under Chairman Bob Pons' Leadership, Planning to Chase Next?

Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, “Murchinson” or “we”), a significant shareholder with...

Form PREC14A - Preliminary proxy statements, contested solicitations

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material